REVATIO: payments to doctors
Payments that named REVATIO as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $13K
- Providers
- 5
- Transactions
- 23
- Average per transaction
- $556
The per-transaction average — $556 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 5 providers the average total is $2,557, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Mylan Inc. | $7,854 | 61.4% |
| Pfizer | $4,932 | 38.6% |